Document Detail


Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.
MedLine Citation:
PMID:  20463739     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The main reason why tumours are not controlled by the immune system is that, unlike pathogens, they do not express potent tumour rejection antigens (TRAs). Tumour vaccination aims at stimulating a systemic immune response targeted to, mostly weak, antigens expressed in the disseminated tumour lesions. Main challenges in developing effective vaccination protocols are the identification of potent and broadly expressed TRAs and effective adjuvants to stimulate a robust and durable immune response. Here we describe an alternative approach in which the expression of new, and thereby potent, antigens are induced in tumour cells by inhibiting nonsense-mediated messenger RNA decay (NMD). Small interfering RNA (siRNA)-mediated inhibition of NMD in tumour cells led to the expression of new antigenic determinants and their immune-mediated rejection. In subcutaneous and metastatic tumour models, tumour-targeted delivery of NMD factor-specific siRNAs conjugated to oligonucleotide aptamer ligands led to significant inhibition of tumour growth that was superior to that of vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing irradiated tumour cells, and could be further enhanced by co-stimulation. Tumour-targeted NMD inhibition forms the basis of a simple, broadly useful, and clinically feasible approach to enhance the antigenicity of disseminated tumours leading to their immune recognition and rejection. The cell-free chemically synthesized oligonucleotide backbone of aptamer-siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use.
Authors:
Fernando Pastor; Despina Kolonias; Paloma H Giangrande; Eli Gilboa
Related Documents :
2986519 - The biology of cell death in tumours.
14632759 - Pleiotropic effects of cxc chemokines in gastric carcinoma: differences in cxcl8 and cx...
18344519 - Tissue inhibitor of metalloproteinases-3 interacts with angiotensin ii type 2 receptor ...
18070419 - Multiplex analysis of cytokines involved in tumour growth and spontaneous regression in...
8265799 - Expression and regulation of the tumour necrosis factor-alpha gene in the female reprod...
15251129 - The role of the cd40 pathway in the pathogenesis and treatment of cancer.
20969869 - Hem-1: putting the "wave" into actin polymerization during an immune response.
18707899 - Involvement of erk-1/2 in il-21-induced cytokine production in leukemia cells and human...
10869769 - Superiority of intramuscular route and full length glycoprotein d for dna vaccination a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nature     Volume:  465     ISSN:  1476-4687     ISO Abbreviation:  Nature     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-13     Completed Date:  2010-06-15     Revised Date:  2012-03-01    
Medline Journal Info:
Nlm Unique ID:  0410462     Medline TA:  Nature     Country:  England    
Other Details:
Languages:  eng     Pagination:  227-30     Citation Subset:  IM    
Affiliation:
Department of Microbiology & Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami Miller School of Medicine Miami, Florida 33134, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, Neoplasm / genetics*,  immunology*
Aptamers, Nucleotide / genetics
Cancer Vaccines / genetics,  immunology,  metabolism
Carrier Proteins / genetics
Cell Line, Tumor
Chickens / genetics
Colonic Neoplasms / genetics*,  immunology*,  pathology
Gene Expression Regulation, Neoplastic
Granulocyte-Macrophage Colony-Stimulating Factor / genetics,  metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Nude
Neoplasm Transplantation
RNA Interference
RNA Stability / genetics*
RNA, Small Interfering / genetics*,  therapeutic use
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
R01 CA138503-04/CA/NCI NIH HHS; R01 CA151857-02/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Aptamers, Nucleotide; 0/Cancer Vaccines; 0/Carrier Proteins; 0/RNA, Small Interfering; 0/Upf2 protein, mouse; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A formal test of the theory of universal common ancestry.
Next Document:  Self-assembly of spider silk proteins is controlled by a pH-sensitive relay.